ArticleWorld journal of microbiology & biotechnology2025
Microbial synthesis of enantiopure (S)-2-methylbutanoic acid via L-isoleucine catabolism in Bacillus spizizenii.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bacillaceae in Probiotics and Postbiotics: Applications, Functional Traits, Mechanisms and Outlook.Probiotics and antimicrobial proteins · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Enantiopure (S)-2-methylbutanoic acid [(S)-2-MBA] is a high-value chiral compound with applications in fragrances, pharmaceuticals, and agrochemicals. However, conventional chemical synthesis lacks stereoselectivity, while existing biosynthetic methods suffer from low yield and purity. Here, we report a novel microbial process using Bacillus spizizenii ATCC 6633 for efficient (S)-2-MBA production via L-isoleucine catabolism. Through targeted screening of rhizospheric soil isolates and Bacillaceae strains, ATCC 6633 demonstrated superior performance, producing 3.67 g/L (S)-2-MBA with 99.32% enantiomeric excess (ee) under optimized conditions (45 °C, 8% inoculation, 5 g/L glucose, and 8 g/L L-isoleucine). A 58.92% conversion efficiency was achieved, and a simplified purification process recovered 63.90% product with 97.32% purity. Mechanistic studies suggested glucose depletion triggered (S)-2-MBA accumulation, aligning with starvation-induced secondary metabolism. This cost-effective, eco-friendly approach eliminates racemic separation steps and harsh reagents, positioning ATCC 6633 as a promising biocatalyst for sustainable (S)-2-MBA production.
Indexed as
Identifiers
40148725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.